Enovis (NYSE:ENOV) Updates FY 2025 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 3.100-3.250 for the period, compared to the consensus estimate of 3.160. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Enovis Trading Up 2.8 %

ENOV stock traded up $1.08 during midday trading on Friday, hitting $39.20. The stock had a trading volume of 64,607 shares, compared to its average volume of 957,561. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The business has a fifty day moving average price of $44.90 and a two-hundred day moving average price of $44.34. Enovis has a 1-year low of $37.60 and a 1-year high of $63.96. The firm has a market cap of $2.23 billion, a P/E ratio of -17.43 and a beta of 1.94.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million during the quarter, compared to analyst estimates of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. On average, sell-side analysts predict that Enovis will post 2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC cut their price objective on shares of Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.